ARTICLE | Finance
Politicizing science
Why 21st Century Cures is a missed chance for change that will politicize NIH
December 14, 2016 1:50 PM UTC
While the FDA reform provisions in the 21st Century Cures Act give the agency backing to carefully advance some of its long-term objectives, an analysis of the bill’s details suggests that when it comes to NIH, at best the legislation is a missed opportunity to make meaningful changes at the world’s largest biomedical funding agency, leaving long-term problems untouched.
At worst, Cures will be a step backward that will politicize research and skew grant-making toward flashy, short-term translational science projects that are not designed to fill the knowledge gaps that prevent biopharma companies from developing scientific advances into new medicines...
BCIQ Company Profiles